About Psy Therapeutics
Psy Therapeutics is a private company based in Boston, Massachusetts. It has reported $10,730,540 raised in two offerings on Form D since October 2019. Its chief executive is David Barlow.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Dec 23, 2021 | Dec 28, 2021amended Sep 12, 2025 | $6,762,848of $20.4M target | 23 | $294K | Debt, Options, Securities on exerciseRule 506(b) | Form D/A ↗3 earlier filings |
| Sep 23, 2019 | Oct 2, 2019 | $3,967,692of $4.2M target | 19 | $208K | EquityRule 506(b) | Form D ↗ |
| Total, two offerings | $10,730,540 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Psy Therapeutics's Form D filed Sep 12, 2025.
DB
David Barlow
Chief Executive Officer and director
PM
Paul Murphy
Director
AC
Alan Cross
Director
WW
William Wagner
Executive officer
JR
Jerry Rosenbaum
Director
DP
Daniel Weiss Pick
Director
JT
Jeff Troderman
Executive officer
Earlier filings also listed Bryan Roberts (director, last listed Oct 2019) and Brant Binder (executive officer and director, last listed Oct 2019).